Vividion Therapeutics, Inc.
Clinical trials sponsored by Vividion Therapeutics, Inc., explained in plain language.
-
New drug hopes to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 01:27 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called VVD-159642 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have not responded to other treatments. The drug works by blocking certain proteins that help cancer grow. The main goals are to find …
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC